Last reviewed · How we verify
FERUMOXIDES
At a glance
| Generic name | FERUMOXIDES |
|---|---|
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
- Back pain
- Pain (all sources)
- Vasodilation
- Hypersensitivity (all sources)
- Back/Leg pain
- Urticaria/Erythematous Rash
- Headache
- Chest pain
- Nausea
- Dyspnea
Serious adverse events
- Anaphylactic and allergic reactions
- Acute moderate to severe pain requiring infusion interruption/discontinuation
Key clinical trials
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging (PHASE1)
- Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases (PHASE2)
- Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy
- A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
- Handheld MPI Imaging to Track Stem Cells in Osteoarthritis (EARLY_PHASE1)
- Virtual Histology of the Bladder Wall for Bladder Cancer Staging (EARLY_PHASE1)
- Sentinel Lymph Node Detection in Gastric Cancer Using a Dual Tracer (Superparamagnetic Iron Oxide and Methylene Blue): A Prospective Study With Histological and OSNA Validation
- Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FERUMOXIDES CI brief — competitive landscape report
- FERUMOXIDES updates RSS · CI watch RSS